What development phase is LASOFOXIFENE TARTRATE in?

LASOFOXIFENE TARTRATE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

LASOFOXIFENE TARTRATE

FDA-approved approved Small molecule Quality 2/100

At a glance

Generic name	LASOFOXIFENE TARTRATE
Modality	Small molecule
Phase	FDA-approved
First approval	2009

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Open-Label Study of Vaginal AZU-101 in Postmenopausal Women (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LASOFOXIFENE TARTRATE CI brief — competitive landscape report
LASOFOXIFENE TARTRATE updates RSS · CI watch RSS